New hope for rare cholesterol disease: drug shows promise in small trial
NCT ID NCT06009393
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 30 times
Summary
This study tested a new medicine called SHR-1918 in 26 adults with homozygous familial hypercholesterolemia (HoFH), a rare genetic condition causing extremely high cholesterol. The goal was to see if the drug could safely lower their LDL (bad) cholesterol after 12 weeks. Participants continued their usual cholesterol treatments while taking SHR-1918.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Xiangya Hospital of Central South University Hospital
Changsha, Hunan, 410007, China
Conditions
Explore the condition pages connected to this study.